Pfizer: Pipeline, Products, Performance, Potential

Date: November 22, 2010
Pages: 228
Price:
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PD59D9DE8FBEN
Leaflet:

Download PDF Leaflet

Pfizer: Pipeline, Products, Performance, Potential
Headquartered in New York, Pfizer has been the world's largest research-based pharmaceutical company since it stole Merck & Co's crown in 1998. The subsequent acquisition of Warner-Lambert (and with it Agouron) in June 2000 and the merger with Pharmacia in April 2003 (which included the former Monsanto division, GD Searle) cemented this position. Furthermore, in October 2009, the company acquired Wyeth, another leading global pharmaceutical company, in a deal valued at around US$68 billion, which should help the company maintain a leadership position in the longer-term.

Pfizer has a broad portfolio, with strengths in the areas of cardiovascular disease, central nervous system disorders, inflammatory disease, metabolic disorders, infectious diseases and oncology.

Employing over 116,500 people worldwide, it has more than 100 overseas subsidiaries and operations in around 150 countries.

Pfizer believes it has one of the broadest product portfolios of all the major pharmaceutical companies. In 2004, Pfizer set an industry record with ten of its products (including Celebrex) generating revenues of more than US$1 billion each; in 2009 this number was reduced to nine.

More Information...

EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting
Cardiovascular/Metabolism
  Champix (varenicline)
  Lipitor (atorvastatin)
  Norvasc (amlodipine)
Central Nervous System
  Aricept (donepezil)
  Geodon/Zeldox (ziprasidone)
  Lyrica (pregabalin)
  Zoloft (sertraline)
Infectious and Respiratory
  Eraxis (anidulafungin)
  Selzentry/Celsentri (maraviroc)
  Vfend (voriconazole)
  Zyvox/Zyvoxa (linezolid)
Urology
  Detrusitol/Detrol (tolterodine)
  Toviaz (fesoterodine)
  Viagra/Revatio (sildenafil)
Arthritis and Pain
  Celebrex/Celebra (celecoxib)
Oncology
  Sutent (sutinib)
Ophthalmology
  Xalatan/Xalcom/Xalacom (latanoprost)
Endocrine Disorders
  Genotropin (recombinant somatropin)
Women's Healthcare
  Fablyn (lasofoxifene)

OPERATIONAL DATA

A wealth of background and detail
  A full 5-year financial performance assessment
  Key corporate events
  Key agreements
  Infrastructure
  Subsidiaries and joint ventures
Latest Results

EXECUTIVE SUMMARY

Introduction
Current Financial Position
  Company Performance
  Business Segment Performance
  Geographic Segment Performance
Company Strategy
  R&D Strategy
  Mergers, Acquisitions and Divestitures
  Key Agreements
    Discontinued Agreements
  Production
  Employees
Product Performance Forecast
  Discontinued Products
Pipeline Analysis
  Discontinued R&D Projects
Other Factors Affecting The Bottom Line
Conclusions / Outlook

THERAPEUTIC AREA FOCUS

R&D PIPELINE

CARDIOVASCULAR / METABOLISM

Marketed Products
  Accupril
  Caduet
  Cardura
  Cordarone
  Fragmin
  Inderal
  Inspra
  Lipitor
  Norvasc
  Teluron
R&D Projects
  Apixaban

CENTRAL NERVOUS SYSTEM

Marketed Products
  Aricept
  Champix
  Cisordinol
  Effexor
  Geodon / Zeldox
  Loramet
  Lyrica
  Neurontin
  Relpax / Relert
  Serax / Seresta
  Xanax
  Zoloft / Lustral / Gladam
R&D Projects
  Bapineuzumab
  Begacestat
  Dimebon
  PF-2545920
  PF-4360365
  PF-5212365
  PF-5236806
  Vabicaserin

VACCINES

Marketed Products
  Acel-Imune
  HibTITER
  Prevnar
  Prevnar
  Tetramune
R&D Projects
  PF-5212366
  PF-5230894

INFECTIOUS AND RESPIRATORY

Marketed Products
  Diflucan
  Eraxis
  Eurartesim
  Minomycin
  Zosyn
  Tygacil
  Vfend
  Zithromax
  Zyvox
R&D Projects
  Filibuvir
  PF-610355
  PH-797804
  R343
  Sulopenem
  TT-033
  Zeven

UROLOGY

Marketed Products
  Enablex
  Viagra
R&D Projects
  PD-299685
  PF-4967544

ARTHRITIS AND PAIN

Marketed Products
  Celebrex
  Enbrel
  Fablyn / Oporia
  Lodine
  Orudis
  rhBMP-2 / InductOs
  Synvisc
  Xiaflex
R&D Projects
  BMP-655
  CP-533536
  PF-4856880
  PF-5212374
  PF-5230895
  PF-5230896
  SD-6010
  Tanezumab
  Tasocitinib

ONCOLOGY

Marketed Products
  Camptosar
  Ellence
  Mylotarg
  Sutent
  Torisel
R&D Projects
  Axitinib
  Bosutinib
  CovX
  Crizotinib
  Figitumumab
  Inotuzumab
  Neratinib
  PD-325901
  PD-332991
  PF-1367338
  PF-3512676
  PF-299804
  PF-3814735
  PF-4217903
  PF-477736
  PF-4856884
  PF-4929113
  PF-562271
  Rindopepimut
  SU14813
  Tremelimumab

OPHTHALMOLOGY

Marketed Products
  Macugen
  Xalatan
  R&D Projects
  PF-4217329
  PF-4382923
  PF-4523655

ENDOCRINE DISORDERS

Marketed Products
Genotropin / Growject

WOMEN’S HEALTHCARE

Marketed Products
  Conbriza
  Microgynon
  Premarin
R&D Projects
  PF-4418948

OTHER

  BeneFIX
  Neumega
  Pantozol
  Rapamune
  Refacto
R&D Projects

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2009

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

Ablynx
Adolor Corporation
Allergan
Almirall SA
Astellas Pharma Inc
Aurobindo Pharma/Claris Lifesciences Ltd
Auxillium Holdings Inc
Bausch & Lomb Inc
Bayer Schering Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Celldex Therapeutics
Coley Pharmaceutical Group Inc
Cytos Biotechnology AG
Eisai
Elusys Therapeutics
Ensemble Discovery
Five Prime Therapeutics Inc
Flamel Technologies Inc
Genentech Inc
GlaxoSmithKline
Graceway Pharmaceuticals LLC
Hydra Biosciences Inc
Icagen Inc
Immunicon Corporation
IMPAX Laboratories Inc
Incyte Corporation
International Partnership for Microbicides
Isis Pharmaceuticals Inc
Lavipharm Co
Ligand Pharmaceuticals Inc
Kosan Biosciences
Medarex Inc
Medivation Inc
Melior Discovery Inc
Merck KGaA
MicuRX Pharmaceuticals/Cumencor Pharmaceuticals
NicOx SA
NovaMed Pharmaceuticals Inc
Novocell
Noxxon Pharma AG
Odyssey Thera Inc
Onyx Pharmaceuticals Inc
OSI Pharmaceuticals Inc/New York University
Protalix Biotherapeutics
Quark Pharmaceuticals Inc
Recordati
Renovis Inc
Rigel Pharmaceuticals Inc
Sigma-Tau Pharmaceuticals Inc
Silence Therapeutics
Strides Arcolab
Tacere Therapeutics
Taisho Pharmaceutical
Takeda
TransTech Pharma
UCB
Others

APPENDIX 4 - INFRASTRUCTURE

Manufacturing Facilities
R&D Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES

Subsidiaries
Joint-venture Companies

APPENDIX 6 - PRODUCT INDEX

LIST OF TABLES

Capital Expenditure By Business Area
Sales By Business Area
Operating Income By Business Area
Identifiable Assets By Business Area
Sales By Destination
Long-Lived Assets By Geographical Area
Key Patent Expiry Dates
Recent Product Approvals
Sales By Therapeutic Area/Major Products
Prevnar/Prevenar Franchise Sales (2008-2016)
Prevnar/Prevenar Franchise Sales (2008-2016)
Tygacil Sales (2008-2016)
Zithromax Total Sales (2008-2016)
Linezolid Sales by Region (2009-2016)
FDA ANDA Approvals for Irinotecan
Sutent Sales by Indication (2008-2015)
Torisel Sales by Indication (2008-2015)
Axitinib Treatment-Related Adverse Events
Axitinib Sales by Indication (2012-2015)
Crizotinib Sales by Indication (2013-2015)
Pfizer's Major Manufacturing Sites

LIST OF CHARTS

Sales, Costs and Operating Income
R&D Expenditure and Capital Expenditure
Capital Expenditure By Business Area
Sales By Business Area
Operating Income By Business Area
Sales By Destination
Employees and Productivity
Sales of Current Top Ten Products (2008-2016)
Top Selling Products, 2009
Lipitor Sales (2008-2016)
Pfizer's Sales of Norvasc (2008-2016)
DSP's Sales of Amlodin (2008-2016)
Apixaban Total Sales (2011-2016)
Pfizer's Sales of Aricept (2008-2016)
Champix Sales (2008-2016)
Geodon/Zeldox Sales (2008-2016)
Lyrica Sales (2008-2016)
Zoloft Sales (2008-2016)
Prevnar/Prevenar (7-valent) Sales (2008-2016)
Prevnar/Prevenar (13-valent) Sales (2010-2016)
Tygacil Sales (2008-2016)
Vfend Sales (2008-2016)
Zyvox Sales (2008-2016)
Detrol/Detrol LA Sales (2008-2016)
Viagra Sales (2008-2016)
Pfizer's Sales of Celebrex (2008-2016)
Astellas' Sales of Celecox (2008-2016)
Amgen's Enbrel Sales (2008-2016)
Pfizer's Sales of Enbrel (2008-2016)
Takeda's Sales of Enbrel (2008-2016)
Pfizer's Camptosar Sales (2008-2016)
Daiichi Sankyo's Topotecin Sales (2008-2016)
Sutent Mode of Action
Sutent Total Sales (2008-2015)
Sutent Sales by Indication, 2008
Sutent Sales by Indication, 2015
Torisel’s Mode of Action
Torisel Sales (2008-2015)
Torisel Sales by Indication (2015)
Axitinib Sales (2012-2015)
Axitinib RCC Sales (2012-2015)
Crizotinib Sales (2013-2015)
PF-3512676 Mechanism of Action Through TLR modulation
Xalatan/Xalcom Sales (2008-2016)
Pfizer's Sales of Genotropin (2008-2016)
Conbriza / Viviant Sales (2010-2016)
Premarin Family Sales (2008-2016)
BeneFIX Sales (2008-2016)
ReFacto/Xyntha Sales (2008-2016)
ReFacto/Xyntha Sales (2008-2016)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity
Skip to top


UCB: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 82 pages
Eli Lilly: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 142 pages
Kyowa Hakko: Pipeline, Products, Performance, Potential US$ 1,040.00 Aug, 2009 · 84 pages
Merck & Co: Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2009 · 186 pages

Ask Your Question

Pfizer: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: